论文部分内容阅读
目的介绍去唾液酸糖蛋白受体(asialoglycoprotein receptor,ASGPR)介导的药物和基因肝靶向作用和机制,及其在治疗肝癌和乙型肝炎实验研究方面的最新进展。方法查阅和选取针对性强、相关度高的文献,总结和归纳ASGPR介导的药物和基因肝靶向用于治疗肝癌和乙型肝炎的最新研究进展。结果ASGPR是肝细胞的一种重要且高效的内吞受体,可用于介导药物和基因的肝靶向递送。结论ASGPR介导的药物和基因肝靶向有望成为肝癌和乙型肝炎治疗的有效手段。
OBJECTIVE: To introduce the ASGPR-mediated drug-gene-targeted liver-targeting and its mechanism and its recent progress in the experimental study on the treatment of hepatocellular carcinoma and Hepatitis B virus. Methods To review and select the literature with strong pertinence and high relevance, and to summarize and summarize the latest progress of ASGPR-mediated drug and gene liver targeting for hepatocellular carcinoma and hepatitis B treatment. Results ASGPR is an important and efficient endocytic receptor for hepatocytes that can be used to mediate liver-targeted delivery of drugs and genes. Conclusion ASGPR-mediated drug and gene liver targeting is expected to become an effective treatment for hepatocellular carcinoma and hepatitis B treatment.